Selected research
Industry Research
Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Research Report 2026
Market perspective
The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Chimeric Antigen Receptor (CAR) T-Cell Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Chimeric Antigen Receptor (CAR) T-Cell Therapy include Allogene Therapeutics, Autolus Therapeutics, Bluebird Bio, CARsgen Therapeutics, Cellectis, Celyad, FOSUNKite, JW Therapeutics and Mustang Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Company
Allogene Therapeutics
Autolus Therapeutics
Bluebird Bio
CARsgen Therapeutics
Cellectis
Celyad
FOSUNKite
JW Therapeutics
Mustang Bio
Sorrento Therapeutics
Bristol-Myers Squibb
Gilead Sciences
Novartis
J & J
Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Type
CD19-targeted
BCMA-targeted
Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Application
Lymphoma
Multiple Myeloma
Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chimeric Antigen Receptor (CAR) T-Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Chimeric Antigen Receptor (CAR) T-Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CD19-targeted
- BCMA-targeted
Applications
- Lymphoma
- Multiple Myeloma
Companies covered
- Allogene Therapeutics
- Autolus Therapeutics
- Bluebird Bio
- CARsgen Therapeutics
- Cellectis
- Celyad
- FOSUNKite
- JW Therapeutics
- Mustang Bio
- Sorrento Therapeutics
- Bristol-Myers Squibb
- Gilead Sciences
- Novartis
- J & J
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CD19-targeted
- 2.2.3 BCMA-targeted
- 2.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Lymphoma
- 2.3.3 Multiple Myeloma
- 2.4 Assumptions and Limitations
3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Breakdown Data by Type
- 3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Type (2027-2032)
4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Breakdown Data by Application
- 4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Perspective (2021-2032)
- 5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Growth Trends by Region
- 5.2.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Dynamics
- 5.3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Trends
- 5.3.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
- 5.3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Challenges
- 5.3.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Chimeric Antigen Receptor (CAR) T-Cell Therapy Players by Revenue
- 6.1.1 Global Top Chimeric Antigen Receptor (CAR) T-Cell Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Chimeric Antigen Receptor (CAR) T-Cell Therapy Head Office and Area Served
- 6.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Players, Product Type & Application
- 6.5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Manufacturers Established Date
- 6.6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
- 7.2 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
- 7.4 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
- 8.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
- 8.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
- 10.2 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
- 10.4 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Allogene Therapeutics
- 12.1.1 Allogene Therapeutics Company Information
- 12.1.2 Allogene Therapeutics Business Overview
- 12.1.3 Allogene Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.1.4 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.1.5 Allogene Therapeutics Recent Developments
- 12.2 Autolus Therapeutics
- 12.2.1 Autolus Therapeutics Company Information
- 12.2.2 Autolus Therapeutics Business Overview
- 12.2.3 Autolus Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.2.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.2.5 Autolus Therapeutics Recent Developments
- 12.3 Bluebird Bio
- 12.3.1 Bluebird Bio Company Information
- 12.3.2 Bluebird Bio Business Overview
- 12.3.3 Bluebird Bio Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.3.4 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.3.5 Bluebird Bio Recent Developments
- 12.4 CARsgen Therapeutics
- 12.4.1 CARsgen Therapeutics Company Information
- 12.4.2 CARsgen Therapeutics Business Overview
- 12.4.3 CARsgen Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.4.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.4.5 CARsgen Therapeutics Recent Developments
- 12.5 Cellectis
- 12.5.1 Cellectis Company Information
- 12.5.2 Cellectis Business Overview
- 12.5.3 Cellectis Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.5.4 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.5.5 Cellectis Recent Developments
- 12.6 Celyad
- 12.6.1 Celyad Company Information
- 12.6.2 Celyad Business Overview
- 12.6.3 Celyad Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.6.4 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.6.5 Celyad Recent Developments
- 12.7 FOSUNKite
- 12.7.1 FOSUNKite Company Information
- 12.7.2 FOSUNKite Business Overview
- 12.7.3 FOSUNKite Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.7.4 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.7.5 FOSUNKite Recent Developments
- 12.8 JW Therapeutics
- 12.8.1 JW Therapeutics Company Information
- 12.8.2 JW Therapeutics Business Overview
- 12.8.3 JW Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.8.4 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.8.5 JW Therapeutics Recent Developments
- 12.9 Mustang Bio
- 12.9.1 Mustang Bio Company Information
- 12.9.2 Mustang Bio Business Overview
- 12.9.3 Mustang Bio Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.9.4 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.9.5 Mustang Bio Recent Developments
- 12.10 Sorrento Therapeutics
- 12.10.1 Sorrento Therapeutics Company Information
- 12.10.2 Sorrento Therapeutics Business Overview
- 12.10.3 Sorrento Therapeutics Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.10.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.10.5 Sorrento Therapeutics Recent Developments
- 12.11 Bristol-Myers Squibb
- 12.11.1 Bristol-Myers Squibb Company Information
- 12.11.2 Bristol-Myers Squibb Business Overview
- 12.11.3 Bristol-Myers Squibb Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.11.4 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.11.5 Bristol-Myers Squibb Recent Developments
- 12.12 Gilead Sciences
- 12.12.1 Gilead Sciences Company Information
- 12.12.2 Gilead Sciences Business Overview
- 12.12.3 Gilead Sciences Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.12.4 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.12.5 Gilead Sciences Recent Developments
- 12.13 Novartis
- 12.13.1 Novartis Company Information
- 12.13.2 Novartis Business Overview
- 12.13.3 Novartis Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.13.4 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.13.5 Novartis Recent Developments
- 12.14 J & J
- 12.14.1 J & J Company Information
- 12.14.2 J & J Business Overview
- 12.14.3 J & J Revenue in Chimeric Antigen Receptor (CAR) T-Cell Therapy Business (2021-2026)
- 12.14.4 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Portfolio
- 12.14.5 J & J Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst